Immunomodulators ( drugs that modulate immune response)

1. Immunomodulators(drugs that modulate immune response) Dr. Kaukab Azim

2. Drug List

3. Immune System • Functions to protect the host from harmful foreign molecules • Inappropriate activation of immune cells can result in autoimmune disorders • Allograft introduction can elicit a damaging immune response • Immune system include two main arms 1) Cell –mediated immunity 2) Humoral (antibody –mediated immunity)

5. Cytokines • Cytokines are soluble signaling proteins that bind to cell surface receptors on a variety of cells • Cytokines include • Interleukins(IL) • Interferons (IFNs) • Tumor Necrosis Factors (TNFs) • Transforming Growth Factors (TGFs) • Colony-stimulating factors (CSFs)

6. IL-2 stimulates the proliferation of antigen-primed (helper) T cells. Cell-mediated Immunity • Activate • NK cells (kill tumor & virus-infected cells). • Cytotoxic T cells (kill tumor & virus-infected cells). • Macrophages (kill bacteria).

7. HumoralImmunity B-lymphocytes TH2 produces (interleukins) IL-4 & IL-5 which in turn causes: •  B cells proliferation & differentiation into • memory B cells • Antibody secreting plasma cells

8. Immunosuppressant Drugs

9. General Features • Immunosuppressantdrugssuppressprimary immune responses(i.e antigen processing, cell proliferation, lymphokine synthesis, etc.) more effectively than secondary immune responses (i.e. those related to re-encountering antigen, that is those related to immunologic memory) • Immunosuppressant drugs are highly effective in treating conditionssuch as organtransplantrejectionand severeautoimmunedisorders. • Immunosuppressant drugs work better if they are given before rather than after the exposure of the body to the antigen (unfortunately most autoimmune diseases are treated after autoimmunity is established). • Therapies with these drugs often require lifelong use, so exposing the patient to increased risk of infections and some cancers (lymphomas, Kaposi’ssarcoma, skin cancer).

10. CYCLOSPORINE Mechanism of action • The drug binds to cyclophilin to form a complex which in turn binds to calcineurin, a cytoplasmic phosphatase, and inhibits its action. • Since calcineurin regulates the ability of a nuclear factor of activated T cells (NFAT)to translocate to the nucleus and increase the production of interleukin-2, the production of IL-2 is suppressed. • As a consequence T-helper cells cannot proliferate and die by apoptosis.

11. Pharmacokinetics • The drug is given PO or IV. • It is totally metabolized by the CYP3A system (its metabolism is affected by a lot of drugs that inhibit or induce the p450 system). • Toxicity • Nephrotoxicity (up to 80%). • Neurotoxicity, including paresthesias (up to 50%) tremor (up to 55%), hallucinations and seizures • Hypertension (up to 50%) • Hirsutism(common), gingival hyperplasia (up to 20%)

12. Therapeutic uses Clinical uses • Organtransplantation (to prevent rejection) (Graft-versus-host disease). • Selected autoimmune disorders ( psoriasis, rheumatoid arthritis, IBD, SLE)

13. TACROLIMUS (FK506) • a fungal macrolide antibiotic. • Chemically not related to cyclosporine • both drugs have similar mechanism of action. • The internal receptor for tacrolimus is immunophilin ( FK-binding protein, FK-BP). • Tacrolimus-FKBP complex inhibits calcineurin.

14. Sirolimus (Rapamycin) Mechanism of action • The drug resembles tacrolimus and binds to the same intracellular Fk binding proteins. However, whereas tacrolimus and cyclosporine block IL-2 gene transcription, sirolimus acts later to block IL-2dependent lymphocyteproliferation. • This blockade is likely due to the inhibition of mammalian kinase, an enzyme which is essential for cell-cycle progression. Therefore the drug inhibits substantially T and B cell proliferation.

16. Sirolimus Pharmacokinetics • The drug is given orally. • It is totally metabolized by the CYP3A4 system. Toxicity • Hyperlipidemia (up to 50%). • Hypertension(up to 50%). • Anemia, leukopenia, thrombocytopenia. Clinical uses • Organtransplantation (to prevent rejection) • Atopicdermatitis, psoriasis

17. Cytotoxic drugs • Inhibitors of purine or pyrimidine synthesis (Antimetabolites): • Azathioprine • MyclophenolateMofetil • Leflunomide • Methotrexate

18. AZATHIOPRINE CHEMISTRY: • Derivative of mercaptopurine. • Prodrug. • Cleaved to 6-mercaptopurine then to 6-mercaptopurine nucleotide, thioinosinic acid (nucleotide analog). • Inhibits de novo (new) synthesis of purines required for lymphocytes proliferation. • Prevents clonal expansion of both B and T lymphocytes.

20. Pharmacokinetics • orally or intravenously. • Widely distributed but does not cross BBB. • Metabolized in the liver to 6-mercaptopurine or to thiouric acid (inactive metabolite) by xanthine oxidase. • excreted primarily in urine. Drug Interactions • Co-administration of allopurinol with azathioprine may lead to toxicity due to inhibition of xanthine oxidase by allopurinol.

21. USES • Acute glomerulonephritis • Systemic lupus erythematosus • Rheumatoid arthritis • Crohn’ s disease.

22. Adverse Effects • Bone marrow depression: leukopenia, thrombocytopenia. • Gastrointestinal toxicity. • Hepatotoxicity. • Increased risk of infections.

23. MYCOPHENOLATE MOFETIL • Is a semisynthetic derivative of mycophenolic acid from fungus source. • Prodrug; is hydrolyzed to mycophenolic acid. Mechanism of action: • Inhibits de novo synthesis of purines. • mycophenolic acid is a potent inhibitor of inosine monophosphate dehydrogenase (IMP), crucial for purine synthesis deprivation of proliferating T and B cells of nucleic acids.

24. Pharmacokinetics: • Given orally, i.v. or i.m. • rapidly and completely absorbed after oral administration. CLINICAL USE: • Solid organ transplants for refractory rejection. • Steroid-refractory hematopoietic stem cell transplant patients. • Combined with prednisone as alternative to cyclosporine or tacrolimus. • Rheumatoid arthritis, & dermatologic disorders.

25. ADVERSE EFFECTS: • GIT toxicity: > 10%. nausea, vomiting, diarrhea, abdominal pain. • Bone marrow suppression > 20% Contraindicated during pregnancy

26. Antibodies Block T cell surface molecules involved in signaling immunoglobulins • antilymphocyte globulins (ALG). • antithymocyte globulins (ATG). • Rho (D) immunoglobulin. • Basiliximab • Daclizumab

27. Muromonab – CD3 • Is a murine monoclonal antibody • Prepared by hybridoma technology • Directed against glycoprotein CD3 antigen of human T cells. • Given I.V. • Metabolized and excreted in the bile.

28. Mechanism of action • The drug binds to CD3 proteins on T lymphocytes (antigen recognition site) leading to disruption of T-lymphocyte function, their depletion and decreased immune response. • Prednisolone, diphenhydramine are given to reduce cytokine release syndrome.

29. Uses • Used for treatment of acute renal allograft rejection & steroid-resistant acute allograft • To deplete T cells from bone marrow donor prior to transplantation. Adverse effects • Anaphylactic reactions (infusion related). • Pulmonary edema • Secondary malignancy • Infection • Cytokine release syndrome (Flu-like illness to shock like reaction).

30. Rho (D) immune globulin • Rho (D) is a concentrated solution of human IgG containing higher titer of antibodies against Rho (D) antigen of red cells. • Given to Rh-negative mother within 24-72 hours after delivery of Rh positive baby (2 ml, I.M.) to prevent hemolytic disease of the next Rh positive babies (erythroblastosisfetalis). Adverse Effects • Local pain • Fever

31. Thalidomide • A sedative drug. • Teratogenic • Can be given orally. • Has immunomodulatory actions • Inhibits TNF-α • Reduces phagocytosis by neutrophils • Increases IL-10 production • Inhibits angiogenesis. • Used in multiple myeloma

32. USES • Myeloma • Rheumatoid arthritis • Graft versus host disease. • Leprosy reactions • treatment of skin manifestations of lupus erythematosus

33. CLINICAL USES OF IMMUNOSUPPRESSIVE AGENTS

35. Immunostimulants

36. INTERFERONS Three families: • Type I IFNs ( IFN-α, β ): • Acid-stable proteins • induced by viral infections • leukocyte produces IFN-α • Fibroblasts & endothelial cells produce IFN-β • Type II IFN (IFN-γ): • Acid-labile • Produced by Activated T lymphocytes.

37. Interferon Effects: IFN- γ : Immune Enhancing • increased antigen presentations with macrophage, natural killer cell, cytotoxic T lymphocyte activation IFN- α, β: • effective in inhibiting cellular proliferation (more effective than IFN- γin this regard)

38. INTERFERONS • Recombinant DNA cloning technology. • Antiproliferative activity. • Antiviral action • Immunomodulatory effect.

39. USES: • Treatment of certain infections e.g. Hepatitis C (IFN- α ). • Autoimmune diseases e.g. Rheumatoid arthritis. • Certain forms of cancer e.g. melanoma, renal cell carcinoma. • Multiple sclerosis (IFN- β): reduced rate of exacerbation. SE: • Fever, chills, myelosuppression.

40. Aldesleukin Mode of action • The drug is a recombinant version of interleukin-2. • It induces proliferation of B and T cells (including cytotoxic T cells) and activation of natural killer cells and lymphokine-activated killer cells. • The mechanism of antitumor activity is unknown but is probably related to the activation of cytotoxic T cells. Toxicity • Hypotension (70%),sinus tachycardia (70%), pulmonary congestion (50%) and edema (50%). • Acute renalfailure(60%) • Mental status changes (70%) • Nausea/vomiting and diarrhea (70%) • Anemia, thrombocytopenia (70%). Clinical uses • Renal cell carcinoma, malignant melanoma

41. Disease modifying anti-rheumetic drugs (DMARDs) • DMARDs are used in the treatment of Rheumotoid arthritis (RA) and have been shown to slow the course of the disease and prevent further destruction of the joints and involved tissues

42. LEFLUNOMIDE • A prodrug • Active metabolite undergoes enterohepatic circulation. • Has long duration of action. • Can be given orally • antimetabolite immunosuppressant. • Pyrimidine synthesis inhibitor • Approved only for rheumatoid arthritis

43. Adverse effects • Elevation of liver enzymes • Renal impairment • Teratogenicity • Cardiovascular effects (tachycardia).

44. Methotrexate • a folic acid antagonist • Orally, parenterally (I.V., I.M). • Excreted in urine. • Inhibits dihydrofolatereductase required for folic acid activation (tetrahydrofolic) • Inhibition of DNA, RNA & protein synthesis • Interferes with T cell replication. • Rheumatoid arthritis & psoriasis and Crohn disease • Graft versus host disease

45. Adverse effects • Nausea-vomiting-diarrhea • Alopecia • Bone marrow depression • Pulmonary fibrosis • Renal & hepatic disorders

47. Hydroxychloroquine • Used for early, mild RA and has relatively few side effects • Does not slow joint damage, therefore it is often used in combination with methotrexate • Mechanism of action may include inhibition of phospholipase A2 , platelet aggregation and effects on the immune system

48. Gold Salts • Cannot repair existing damage, only prevent further injury • Gold compounds are used infrequently due to constant monitoring for serious toxicity • Currently available gold preparation is auranofin, given orally • Auranofin is taken up by macrophages and suppresses phagocytosis and lysosomal enzyme activity resulting in slower progression of bone and articular destruction

49. Biological therapies in RA • IL-1 and TNF-a are proinflammatory cytokines involved in the pathogenesis of RA • TNF inhibitors (etanercept, adalimumab and infliximab) • IL-1 receptor antagonist (anakinra)

50. Infliximab • Monoclonal antibody that binds specifically to TNF-a, thereby neutralizing the cytokine • Approved for use in combination in patients with RA who have had inadequate response to methotrexate monotherapy • Not indicated for use alone, because it allows the body to develop anti-infliximab antibodies which reduces efficacy